Status:
COMPLETED
Sirolimus Treatment for Refractory PRCA
Lead Sponsor:
Bing Han
Conditions:
Pure Red Cell Aplasia
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Pure red cell aplasia (PRCA) is a kind of anemia characterized by severe reticulocytopenia and obvious bone marrow erythroblastic cells decreased. Cyclosporine and /or steroids are the first line ther...
Detailed Description
Pure red cell aplasia (PRCA) is a rare normocytic normochromic anemia with reticulocytopenia, characterized by a reduction of erythroid precursors from the bone marrow, could be divided into congenita...
Eligibility Criteria
Inclusion
- Refractory pure red cell aplasia.
- Excluding other diseases which might cause hematological abnormalities.
- No response or intolerant to first and second line therapies.
- 18-80 years old.
- All subjects must: agree not to donate blood or be counseled about pregnancy precautions and risks of fetal exposure.
- Written informed consent.
Exclusion
- NOT refractory pure red cell anemia.
- Response and well tolerate to first or second line therapy.
- Patients who are under 18-year-old or over 80-year-old.
- Pregnant or lactating.
- Patients unwilling to or unable to comply with the protocol.
Key Trial Info
Start Date :
February 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2021
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT03364764
Start Date
February 1 2018
End Date
May 1 2021
Last Update
July 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730